Gemphire Therapeutics Inc. (GEMP) Trading at $10.11 after Rise on Jun, 29

June 29, 2018 - By Ashley Bratcher

Gemphire Therapeutics Inc. (NASDAQ:GEMP) trading at $10.11 after increase. The move was reported on Jun, 29 by Barchart.com. The company has $143.89M market cap. At $10.72 PT, the company’s valuation could be $8.63 million more.

On August, 13 is anticipated Gemphire Therapeutics Inc. (NASDAQ:GEMP)’s earnings report, Zacks reports. Analysts expect change of 22.97 % or $0.17 from previous year’s $-0.74 EPS compared to current’s $-0.57 EPS. Wall Street sees -1.72 % EPS growth as of August, 13.

For more Gemphire Therapeutics Inc. (NASDAQ:GEMP) news brought out briefly go to: Benzinga.com, Streetinsider.com, Benzinga.com, Benzinga.com or Streetinsider.com. The titles are as follows: “Benzinga Pro’s 5 Stocks To Watch Today” brought out on June 29, 2018, “After-Hours Stock Movers 06/28: (GEMP) (NKE) (VRTX) Higher; (SNX) (CVG) Lower (more…)” on June 28, 2018, “5 Stocks Moving In Thursday’s After-Hours Session” with a publish date: June 21, 2018, “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” and the last “Pre-Open Movers 06/29: (GEMP) (DERM) (NKE) Higher; (PFIE) (STZ) (SNX) Lower (more…)” with publication date: June 29, 2018.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis .The company has $143.89 million market cap. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH.Currently it has negative earnings.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: